- Abstract:
-
There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. Recently, a subset of these same mutations of ACVR1 have been identified in diffuse intrinsic pontine glioma (DIPG) tumors. Here we describe the structure-activity relationship for a series of novel ALK2 inhibitors based on the 2-aminopyridine compound K0...
Expand abstract - Publication status:
- Published
- Journal:
- Journal of medicinal chemistry
- Volume:
- 57
- Issue:
- 19
- Pages:
- 7900-7915
- Publication date:
- 2014-10-05
- DOI:
- EISSN:
-
1520-4804
- ISSN:
-
0022-2623
- URN:
-
uuid:f6d3956a-8f1b-41b4-9e3d-1d9efe0fc35f
- Source identifiers:
-
479273
- Local pid:
- pubs:479273
- Language:
- English
- Keywords:
- Copyright date:
- 2014
Journal article
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record